Clinical trials · Nashville, TN
Non Small Cell Lung Cancer clinical trials in Nashville
We’re tracking 120 recruiting non small cell lung cancer studies with a site in or near Nashville — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Nashville
- NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Nashville, TennesseeAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Nashville, TennesseeAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Nashville, TennesseeAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Nashville, TennesseeAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Nashville, TennesseeAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Nashville, TennesseeAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Nashville, TennesseeAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Nashville, TennesseeAges 12 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Nashville, TennesseeAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Nashville, TennesseeAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Nashville, TennesseeAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Nashville, TennesseeAges 18 years+ - NCT06046495RecruitingPhase 1
Study of an oral EGFR inhibitor for non-small cell lung cancer
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
Nashville, TennesseeAges 18 years+ - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Nashville, TennesseeAges 18–100 - NCT07555210Recruiting
Bone Density Changes During Cancer Immunotherapy
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Nashville, TennesseeAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Nashville, TennesseeAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Nashville, TennesseeAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
Nashville, TennesseeAges 18 years+ - NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Nashville, TennesseeAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Nashville, TennesseeAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Nashville, TennesseeAges 18 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Nashville, TennesseeAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Nashville, TennesseeAges 18 years+
Hear when a new Non Small Cell Lung Cancer trial opens near Nashville, TN
We’ll email you when one opens near Nashville, TN — at most once a week, no account needed, unsubscribe anytime.
Non Small Cell Lung Cancer trials in other cities
Where these studies are running near Nashville
Institutions with a site for the recruiting non small cell lung cancer studies listed above.
- Sarah Cannon Research Institute · 9 studies
- SCRI Oncology Partners · 7 studies
- Vanderbilt University Medical Center · 6 studies
- Tennessee Oncology · 4 studies
- Exelixis Clinical Site
- Local Institution - 0697
- Research Site
- SCRI
What taking part in a non small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting non small cell lung cancer studies in Tennessee.
Common questions
- Are there non small cell lung cancer clinical trials near Nashville?
- Yes. We're currently tracking 120 recruiting non small cell lung cancer studies with a site near Nashville, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non small cell lung cancer study near Nashville?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Nashville to take part?
- Not necessarily. These studies have a site near Nashville, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non small cell lung cancer studies open near Nashville regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.